Future of Helicobacter pylori and its feasibility.
Talebi Bezmin Abadi A , Kusters JG 
Expert Rev Anti Infect Ther.2018 Sep 13 ; ():.
PubMedで表示
Google翻訳で開く
(47view , 0users)
Full Text Sources
- 要約はありません -
PMID: 30211621 [PubMed - as supplied by publisher]
関連論文
- Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study.
- Vonoprazan versus conventional proton pump inhibitor-based triple therapy as first-line treatment against Helicobacter pylori: A multicenter retrospective study in clinical practice.
- Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication.
- Vonoprazan, a Novel Potassium-Competitive Acid Blocker, Should Be Used for the Helicobacter pylori Eradication Therapy as First Choice: A Large Sample Study of Vonoprazan in Real World Compared with Our Randomized Control Trial Using Second-Generation Proton Pump Inhibitors for Helicobacter pylori Eradication Therapy.